STARTUP PROFILE

Paradromics

COUNTRY

USA

FOUNDED

2016

CATEGORY

Brain-Computer Interface

Developing the Connexus, a fully implantable, high–data-rate BCI that records single-neuron brain signals to restore communication in paralyzed patients.

Visit website →

← Back to Startups

•

Neurofounders Insights

$ Funding -

Series B

MODALITY

Intracortical

FORM FACTOR

Implant

INTERFACE DEPTH

Implantable

INDICATION

Communication

TARGET USER

Patients

REGULATORY STAGE

Investigational

Paradromics is one of the most serious competitors in the high-bandwidth implantable BCI category, emphasizing single-neuron recording and communication restoration. It is often framed as a peer to Neuralink, though with a more tightly defined initial use case and lower public visibility.

Related companies

•

Mentioned in Market Notes

MOST RECENT COVERAGE

The Big June Data Dump

9 June – 23 June 2026

Paradromics completed the first surgical implantation of its Connexus brain-computer interface in the FDA-approved Connect-One feasibility study at University of Michigan Health. The study is among the first to target speech restoration and builds on a temporary implant that the same surgical team placed during epilepsy research in 2025. It is the first chronic Connexus implant since Paradromics secured its IDE in November 2025.